Weight loss drugs boost retail pharmacy sales
A pharmacist displays boxes of Ozempic, a semaglutide injection drug used for treating type 2 diabetes made by Novo Nordisk, at Rock Canyon Pharmacy in Provo, Utah, U.S. March 29, …
A pharmacist displays boxes of Ozempic, a semaglutide injection drug used for treating type 2 diabetes made by Novo Nordisk, at Rock Canyon Pharmacy in Provo, Utah, U.S. March 29, …
An ADSEP with blue PIL-BOXs, hardware which will be delivered to Sierra Space for the LIFE habitat pathfinder mission. Redwire Space infrastructure company Redwire is putting a biotech technology testbed …
The impact of new weight loss treatments is being felt well beyond the health-care industry . Analysts used the ritual of quarterly earnings calls to probe companies on whether their …
Since the CNBC Investing Club’s July Monthly Meeting, the stock market has seesawed up and then down on a slew of quarterly earnings results and inflation data. That’s left Wall …
A box of the diabetes drug Ozempic rests on a pharmacy counter in Los Angeles, April 17, 2023. Mario Tama | Getty Images Blockbuster weight-loss drugs are priced significantly higher …
The extraordinary activist-investor interest in Salesforce (CRM) eased further in the second quarter, according to the latest regulatory filings from influential Wall Street pros. These big-name investors also made moves …
Here’s our Club Mailbag email [email protected] — so you send your questions directly to Jim Cramer and his team of analysts. We can’t offer personal investing advice. We will only …
CNBC’s Jim Cramer on Tuesday gave investors his top sectors and stocks to watch as China’s economy slows down. The Dow slid more than 300 points on Tuesday as concerns …
Eli Lilly has had a great run, but UBS expects about 16% further upside in the coming months as a steady stream of positive news propels the stock higher and …
Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Wednesday’s key moments. Back-to-back losses Still believe in …